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Abstract
Introduction: Poorly differentiated thyroid carcinoma (PDTC, insular carcinoma) occurs rarely. It is described with more aggressive be-
haviour, poorer prognosis, and higher mortality than well differentiated thyroid carcinoma (WDTC).
The aim of this study was to evaluate the clinical course of patients with PDTC, in addition to frequency, clinical stage at the time of
diagnosis and the possibility of radical surgical resection, the necessity and kind of complementary treatment, occurrence of distant me-
tastases, and the survival of patients.
Material and methods: The study involved 14 patients (9 females, 5 males) diagnosed and treated for PDTC between 2000 and 2009, aged
38 to 78 years. The medical records of patients with PDTC were analyzed to estimate assumed parameters according to the purpose of the
study.
Results: PDTC was diagnosed in 14 among 801 patients with thyroid carcinoma (1.75%). Clinical stages (UICC 2002) at the time of diagno-
sis were as follows: 3 patients — pT1-2No-xMx (21.5%); 10 patients — pT3 4Nx o 1Mx-1(71.4%); and 1 was unresectable — TxN1M1 (7.1%). Total
thyroidectomy was achieved in 9 patients (64.3%), and 4 patients (28.6%) received non radical surgery. Complementary radioiodine
treatment was given to 12 patients (85.8%). Radiation therapy of the neck was applied to 7 patients, palliative radiotherapy of the brain to
1 patient, and chemotherapy to 1 patient. Distant metastases to the lung and to the brain at diagnosis were observed in 2 patients (14.3%).
During follow-up of 3–62 months lung metastases were observed in 4 patients (28.6%), three patients were observed above 5 years as
disease-recurrence free (21.5%), but in one patient after 5 years and 2 months distant metastases were diagnosed. Three patients died after
2–30 months (21.5%), 2 patients were lost for control, and in the remaining 6 follow-up lasted for less than 5 years.
Conclusions: Poorly differentiated thyroid carcinoma is still a challenge both for pathologists and clinicians. Infrequent prevalence, more
aggressive course, and poorer prognosis constitute major problems for the clinicians.
(Pol J Endocrinol 2010; 61 (5): 467–473)
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Streszczenie
Wstęp: Niskozróżnicowany rak tarczycy (PDTC, poorly differentiated thyroid carcinoma) występuje rzadko, charakteryzuje się bardziej agre-
sywnym przebiegiem, gorszym rokowaniem, większą śmiertelnością niż wysokozróżnicowane raki tarczycy (WDTC, well differentiated
thyroid carcinoma).
Celem pracy była analiza przebiegu choroby u pacjentów z PDTC z uwzględnieniem częstości występowania, zaawansowania kliniczne-
go przy rozpoznaniu, możliwości chirurgicznego leczenia radykalnego, konieczności i rodzaju leczenia uzupełniającego, wystąpienia
przerzutów odległych, przeżycia chorych.
Materiał i metody: Badaniem objęto 14 chorych (9 kobiet, 5 mężczyzn) z PDTC, zdiagnozowanych i leczonych w latach 2000–2009, wiek
38–78 lat. Przeanalizowano dokumentację medyczną pacjentów z PDTC, oceniając założone w celu pracy parametry.
Wyniki: Niskozróżnicowanego raka tarczycy zdiagnozowano u 14 chorych spośród 801 z rakiem tarczycy (1,75%). Zaawansowanie kli-
niczne (UICC 2002) przy rozpoznaniu 3 chorych: pT1-2No-xMx (21,5%), 10: pT3-4Nx-o-1Mx-1(71,4%), 1 nieoperacyjny: TxN1M1(7,1%). Radykalnie
operowano 9 chorych (64,3%), nieradykalnie 4 (28,6%), jednego (7,1%) zdyskwalifikowano. Leczenie uzupełniające — terapia 131I:
12 (85,8%), 1 zdyskwalifikowany, 1 nie zgłosił się; radioterapia szyi: 7 (50%), paliatywna OUN: 1 (7,1%); chemioterapia: 1 (7,1%).
Przerzuty odległe przy rozpoznaniu stwierdzono u 2 chorych (14,3%), po 3–62 miesiącach: u 4 (28,6%). Przeżycie: 3 chorych ponad
5-letnie (21,5%), u jednego po 62 miesiącach zdiagnozowano przerzuty do płuc; 3 zmarło (21,5%), 2 zaprzestało kontroli, u 6 obserwacja
poniżej 5 lat.
Wnioski: Niskozróżnicowany rak tarczycy wciąż stanowi wyzwanie zarówno dla patologów, jak i klinicystów. Rzadkie występowanie,
bardziej agresywny przebieg i gorsze rokowanie nie ułatwiają opracowania dla tej grupy chorych jednolitych zaleceń terapeutycznych,
które mogłyby poprawić przeżycie. Część z nich może wymagać wielokierunkowego intensywnego leczenia, a ustalenie wskazań do
takiego postępowania nadal pozostaje przedmiotem badań i obserwacji. (Endokrynol Pol 2010; 61 (5): 467–473)
Słowa kluczowe: niskozróżnicowany rak tarczycy, rak wyspowy, rokowanie, leczenie
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Thyroid carcinoma (TC) is the most frequent neoplasm
of endocrine glands. Well differentiated thyroid carci-
nomas (WDTCs) account for up to 90% of all thyroid
carcinoma cases and are characterized by favourable
prognosis when modern treatment is applied [1]. Un-
differentiated (anaplastic) thyroid carcinoma (UDTC)
occurs rarely, but it presents a very aggressive clinical
course with a fast local growth, distant metastases, and
definitely bad prognosis [1]. A 5-year survival is so rare
that after obtaining such a treatment effect, primary
diagnosis revision is usually required [3].
Among patients diagnosed with thyroid carcinoma,
a small group with distinct histopathological and clini-
cal features has been noticed which does not suit either
WDTCs or UDTC. The term ‘poorly differentiated thy-
roid carcinoma’ (PDTC) was suggested for the group of
TCs with intermediate features [4]. According to vari-
ous authors, the incidence of PDTC among patients with
thyroid carcinomas is estimated at the level of 2–3% in
the USA and up to 15% in northern parts of Italy, with
an average of 4–7% for all thyroid carcinomas [5, 6].
Genetic factors are thought to explain the relatively high
prevalence of PDTC in northern Italy and other Alpine
regions of Central Europe [5]. Genetic and/or environ-
mental factors are suggested in the aetiology of PDTC
(including dietary factors, e.g. iodine) [5].
Gene p53 mutations are detectable in approximate-
ly 70–85% of UDTCs and 20–30% of PDTCs, but they
are not found in WDTCs. Thus, mutated p53 is a mo-
lecular marker of thyroid tumour dedifferentiation, sig-
nalling poor prognosis [7–10]. The mutations are most-
ly spontaneous but they may be also a result of previ-
ous radiotherapy or 131I treatment [7].
K-, H-, and N-RAS mutations are other genetic fac-
tors which appear to play a role and are found in near-
ly 10–20% of WDTCs, in 50% of PDTCs, and in a similar
percentage of UDTCs [7, 11]. The role of b-catenin mu-
tations is still controversial. There are data on the oc-
currence of b-catenin mutations in thyroid carcinomas
associated with worse and bad prognosis, observed in
32% of PDTC and 80% of UDTC [7, 12]. However,
Rocha et al. described 17 PDTCs of which none pre-
sented b-catenin mutation, and suggested that loss of
membrane E-cadherin is the crucial event in determin-
ing the dedifferentiation rather than b-catenin muta-
tions [13].
The activating mutation in the BRAF gene was de-
tected in a fraction of poorly differentiated thyroid car-
cinoma developing from differentiated papillary thy-
roid carcinoma (PTC) having some residual foci of pap-
illary carcinoma. Therefore, the presence of BRAF mu-
tation may appear as a prognostic factor of transition
from PTC to PDTC [14, 15]. It is worth noticing that in
a recent study BRAF mutation has been associated to
18FDG PET-positive radioiodine refractory metastases
of PDTC [16].
PDTCs are characterized by a more aggressive clini-
cal course than WDTCs. They are often more clinically
advanced at diagnosis, tend to recur locally, and devel-
op metastases to regional lymph nodes, lungs, and
bones [6]. The prognosis is worse than for WDTCs, but
it is not as bad as for UDTCs. The mean 5-year survival
of patients with PDTCs is approximately 50% while
patients with UDTCs have a mean survival of
6–8 months [6, 17].
The rarity of PDTCs and equivocal diagnostic crite-
ria are the causes of difficulties in establishing uniform
recommendations concerning the therapeutic proce-
dure for this type of tumour. Postoperative 131I treat-
ment, radiotherapy, or chemotherapy are decided on
the basis of individual indications [18, 19].
The aim of this study is to present our own observa-
tions of the clinical course of PDTCs in patients who
were diagnosed and treated during 9 years in one clinic
— the Department of Endocrinology and Nuclear Medi-
cine in cooperation with the Department of Surgical
Pathology, Hollycross Cancer Centre (Świętokrzyskie
Centrum Onkologii, SCO) in Kielce.
Material and methods
The study involved a group of 14 patients diagnosed
histologically with poorly differentiated thyroid carci-
noma (PDTC): nine female patients with ages ranging
from 38 to 78 (mean age 63.2 years) and five males with
ages ranging from 51 to 75 (mean age 63.8 years), who
were treated in SCO in Kielce between 2000 and 2009.
The patients’ medical documentation was analyzed
retrospectively and the frequency of PDTC among all
the thyroid carcinoma patients was taken into consid-
eration. Moreover, the clinical course of PDTC (clinical
stage at the moment of diagnosis, the possibility of radi-
cal surgical treatment, the necessity and type of the com-
plementary treatment applied, occurrence of distant
metastases, and survival of patients) was evaluated.
The first diagnosis of PDTC originates from Novem-
ber 2000. The period of patient follow-up was ranged from
2 to 76 months. The study finished in December 2009.
The clinical advancement at the moment of diagno-
sis was evaluated during the first diagnostics and the
initial treatment - preoperatively, postoperatively, af-
ter complementary 131I treatment with the post-thera-
peutic scintigraphy results, in accordance with the rec-
ommendations of the Polish Group of Endocrine Tu-
mours, including the TNM classification dating from
1992, modified in 2002 [18, 20, 21].
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All histopathological examinations of the patients
operated in SCO were evaluated by two pathologists
from the Department of Surgical Pathology, SCO,
Kielce. Histopathological material taken from two pa-
tients after first surgical treatment performed beyond
SCO was consulted in our centre. The whole comple-
mentary and/or palliative treatment, including 131I treat-
ment, radiotherapy, and chemotherapy, was adminis-
trated in SCO in Kielce. Among 801 thyroid carcinoma
patients 14 were diagnosed with PDTC, 1.75% of our
material. It occurred more often among females (64.3%);
the female:male ratio (F:M) was 1.8:1. Most patients
were ≥ 50 years old at the time of the diagnosis: thir-
teen patients (92.9%) including five males and eight fe-
males. During analysis of the anamnesis preceding the
diagnosis, 11 patients (78.6%) were diagnosed with nod-
ular goiter including two patients with recurrence after
strumectomy. One patient was administered 11.1 mCi
131I because of subclinical hyperthyroidism in the course
of postoperative regrowth of goiter 5 years before thy-
roid carcinoma diagnosis. Five patients (35.7%) were
characterized by quite fast growth of tumour on the
neck, ranging from a few weeks to 4–5 months. Three
patients (21.5%) were diagnosed preoperatively with
thyroid carcinoma because of lymph node metastases.
Results
Clinical advancement at the moment of diagnosis
At the moment of thyroid carcinoma diagnosis, three
patients presented pT1-2No-xMx stage (21.5%) and ten
patients pT3-4Nx-o-1Mx-1 stage (71.4%). One female patient
presented inoperable disease from the very beginning
and was in rather poor general condition with metastas-
es to the regional, mediastinum, and left supraclavicu-
lar lymph nodes and distant metastases to the lung and
brain (TxN1M1).
One female patient was primarily diagnosed with
right thyroid lobe papillary carcinoma at the clinical
stage of pT1aNoMx. As well as the diagnosed micro-
cancer, the presence of a hyalinising trabecular tumour
(diameter of 46 mm) in the left thyroid lobe was found
in the specimen. The occurrence of metastases after
a year and surgical removal of these metastases led to
verification of the diagnosis. Finally, the left thyroid lobe
carcinoma and metastasis to the lungs were diagnosed
as poorly differentiated thyroid carcinoma foci.
The TNM classification of our patients is presented
in Table I.
Surgical treatment
Thirteen patients (92.9%) were qualified for operative
treatment. One female patient (7.1%) was disqualified
because of very poor condition since the beginning of
the disease. Nine patients (64.3%) underwent radical
surgery: total thyroidectomy and lymphadenectomy.
Some patients from this group (4/9; 44.4%) required
surgical radicalisation after the first operative treatment,
including two patients after the first operation not per-
formed in our centre.
Four patients (28.6%) were operated not radically.
In this sub-group, one patient (7.1%) was diagnosed
with an unresectable tumour during the operation, in
the other three patients (21.5%) carcinoma foci exceed-
ed the line of the surgical cut at the histopathological
assessment. In two patients (14.3%) an extensive infil-
tration beyond the thyroid capsule including external
carotid artery, common carotid artery, larynx, and tra-
chea was found.
Postoperative treatment
After the performed surgical treatment, all patients (13/
14; 92.9%) were planned for radioiodine scan and eval-
uation of stimulated serum Tg level. However, one pa-
tient from this group, although he was initially quali-
fied to receive the complementary 131I treatment, did
not attend. One female patient (1/14; 7.1%) was not
qualified because of her very poor general health con-
dition. The remaining 12 patients (85.8%) received 131I
treatment. The endogenous TSH stimulated thyroglo-
bulin level ranged from < 0.2 ng/ml to > 300 ng/ml,
with a mean level of 84.39 ng/ml. In two patients, the
thyroglobulin level was < 0.2 ng/ml, including one pa-
tient with positive antithyroglobulin antibodies.
The radioiodine activity applied for the initial treat-
ment ranged from 2100 MBq (56.75 mCi) to 4884 MBq
(132 mCi). During the follow-up, seven patients (50%)
were qualified to receive further 131I treatment. Four
patients were treated twice with131I, one patient was
treated three times, one was treated four times, and one
was treated six times (total iodine activity 620 mCi). In
the patients who were treated by means of more than
one dose of 131I, the indications for successive doses of
Table I. Clinical stage at the time of diagnosis PDTC — TNM
Tabela I. Zaawansowanie kliniczne w chwili rozpoznania
PDTC — TNM






















131I resulted from persistent 131I neck uptake, and in one
case radioiodine-avid lung metastases.
Seven patients (50%) were qualified to receive ex-
ternal beam radiotherapy, including one female patient
for whom the palliative radiotherapy of neck, mediasti-
num, and brain areas was the only possible treatment
to be applied. Six patients, in whom pT4 and/or N1
(42.9%) stage was diagnosed, were qualified to receive
external radiotherapy of the neck and mediastinum af-
ter the surgical treatment and 131I therapy.
The scheme of the treatment performed in all the
patients with PDTC is presented in Figure 1.
Distant metastases were found in two patients
(14.3%) at the moment of PDTC diagnosis, in one pa-
tient there were metastases to lung and brain, and in
the other there were radioiodine refractory lung me-
tastases. During the follow-up, lung metastases were
diagnosed in four other patients (28.6%). Only in one
of them were the metastases characterized by low io-
dine uptake, and they did not accumulate radioiodine
in the other three patients.
One patient (7.1%) with clinical advancement of
pT3NxMo at diagnosis was referred for chemotherapy
after the radioiodine refractory lung metastases were
found. The patient received doxorubicin and cisplatin
and achieved incomplete remission, he is currently be-
ing considered for tyrosine kinase inhibitor therapy.
In the group of patients with distant metastases to
the lungs, who were diagnosed after the initial treat-
ment, three patients were qualified for thoracic surgi-
cal treatment, in each case the histopathological confir-
mation of PDTC metastases to the lungs was obtained.
The observation course of the patients with distant
metastases is shown in Table II.
Survival of patients
Total duration of follow-up was 9 years and 2 months.
The observation time of individual patients ranged from
2 months to 6 years and 4 months.
Five-year disease-free survival was acquired in three
patients (21.5%). One patient was diagnosed with ra-
dioiodine refractory metastases to the lungs 5 years and
Table II. Clinical course of PDTCs with distant metastases
Tabela II. Przebieg obserwacji u chorych z przerzutami odległymi u chorych z PDTC
Patient gender pTN RtgTh ChTh Presence Follow-up to Total follow-up
age (year) of M1 at dgn presence of M1
S.P.    ,70 pT4N1 + –  (+) lung 15 months
S.W.    ,55 pT4N1 + –  (–) 3 months 30 months: DEATH
E.Ś.    ,68 pT3N1 + –  (–) 5 years 2 months 6 years 4 months
L.K.    ,51 pT3Nx – +  (–) 19 months 4 years 9 months
K.R.    ,56 TxN1 + – (+) lung, brain 2 months: DEATH
Z.T    ,50 pT1No – –  (–) 12 months 20 months
Figure 1. Treatment of patients with PDTC in ŚCO in Kielce





















2 months after initial surgery. During the study three
patients (21.5%) died. Two patients (14.3%) escaped
from control after 2 and 56 months, respectively, and
six patients (42.9%) have been less than 5 years in fol-
low-up.
Discussion
The term of ‘poorly differentiated thyroid carcinoma’
was proposed in 1983 by Sakamoto et al. [4]. They ana-
lyzed 258 malignant thyroid carcinomas and found that
35 of them had non-papillary/non-follicular growth
pattern with poor prognosis. Five-year survival was
observed in 65% of that sub-group compared to 95.1%
of patients with WDTC.
Almost simultaneously, Cargangiu et al. proposed
a similar definition. They reinterpreted a report original-
ly described by Langhans in 1907 and introduced the
name of insular carcinoma to a new type of thyroid car-
cinoma characterized by the presence of insulae which
included small cell size, round/oval hyperchromatic nu-
clei, mitotic activity, and necrotic background [22].
Despite increasing acceptance of the term ‘poorly
differentiated thyroid carcinoma’, for many years vari-
ous authors around the world classified different histo-
logical types to the group of PDTC [4, 23–26]. There-
fore, data in the literature were difficult to analyse mor-
phologically, epidemiologically, and clinically. The new
type of thyroid carcinoma — poorly differentiated thyroid
carcinoma — was defined in the WHO Classification of
Endocrine Tumours as recently as 2004. PDTC is de-
fined as a neoplasm developing from thyroid follicle
cell, presenting restricted differentiation to it and hav-
ing both morphological and biological intermediate
behaviour between well-differentiated thyroid carcino-
mas and undifferentiated carcinoma [27]. PDTC may
develop ‘de novo’ or in the persistent differentiated
thyroid carcinoma.
Uniform histopathologic diagnostic criteria were
reached for PDTC at a consensus conference in Turin,
Italy, in 2006. The proposed criteria, known as the “Turin
criteria”, were published in 2007. According to them,
PDTC is characterised by: 1) the presence of solid/tra-
becular/insular pattern of growth; 2) the absence of the
conventional nuclear features of papillary carcinoma;
3) the presence of at least one of the following micro-
scopic features: convoluted nuclei; mitotic activity ≥ 3 ×
× 10HPF; or tumour necrosis [28].
Diagnosis of poorly differentiated thyroid carcino-
ma should be considered an unfavourable prognostic
factor for patients with thyroid carcinoma. The histo-
pathological type of TC is an important parameter
among accepted prognosis factors associated to a more
aggressive clinical course in TC [29]. Doubtless, PDTC
presents as a separate type in the WHO Classification
of Thyroid Carcinoma; therefore, prognostic factors
specific only to PDTC are still to be determined [27, 30].
A neoplasm with an intermediate morphological and
biological behaviour between WDTCs and UDTC may
be the result of a disturbed cell maturation process. Thus,
it is possible to appreciate for PDTC the unfavourable
prognosis factors known for WDTC.
Male gender is still a controversial prognostic fac-
tor, but poorer prognosis in male patients with WDTC
than in female patients with the same condition pre-
dominates [29]. Since the first studies regarding PDTC,
less significant female predominance has been noted
in comparison to WDTCs. Women are only twice as like-
ly to be diagnosed with PDTC as men [3, 4, 31–33]. It
often occurs in older groups of patients, which may have
an impact on prognosis. An age of 45 years or over is
known to be an unfavourable prognosis factor both for
WDTCs and PDTCs [29, 31–33]. In our study, less than
two thirds of patients with PDTC were of female gen-
der, with significant predominance of patients aged
over 45 years (92.9%). Three patients, who died, were
all older than 45 years (mean age 62 years) and two of
them died of TC.
Volante et al. analyzed a group of 183 PDTCs with
predominant trabecular-insular-solid growth patterns and
demonstrated that the presence of distant metastases
and some histopathological features, e.g. necrosis or
mitotic index > 3 per 10 HPF, were statistically signifi-
cant parameters associated with low 5-year survival rate,
apart from age not less than 45 years [31]. Lai et al. re-
ported similar results of a clinical analysis of a group
composed of 9 of their own patients with insular carci-
noma and 73 others described in other English litera-
ture reports, but without histopathological analysis [32].
The insular type of PDTC is clearly predominant, the
majority of data being related to that sub-group. It is
acceptable that solid/trabecular PDTC may come under
the same diagnosis.
Consecutive studies have reported subsequent prog-
nostic indicators associated with unfavourable outcome
of PDTC, such as high TNM stage, extrathyroidal ex-
tension or infiltration of the trachea, and no post-oper-
ative 131I treatment with more than 30 mCi [33, 34]. Three
patients in the study group showed intra-surgical ad-
vanced local invasion with infiltration of the trachea,
and one of them died of TC after 30 months, a second
one stopped follow-up after 56 months, and a third one
is still being observed a little over one year later. In one
patient from our group, despite satisfactory surgical
management, radioiodine therapy was administered as
late as almost two years after thyroidectomy.
Twelve patients in our study (85.8%) were adminis-
tered with 131I therapy. Various data show that PDTCs
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display the ability to uptake radioiodine in up to
80–85% of cases [3, 10]. In the literature, administration
of 131I appears to be a substantially beneficial therapy if
the tumour shows good radioavidity [31, 33–35]. The
effects of radioiodine therapy observed in patients with
insular carcinoma were more satisfactory than in pa-
tients with predominant solid or trabecular growth pat-
terns of PDTC [35]. However, the majority of studies in
the literature do not confirm the efficacy of 131I therapy
to prolong 5-year survival, regardless of 131I dose or his-
tological variant of PDTC [31–33, 35]. Thus, complemen-
tary 131I therapy ought to be considered in every pa-
tient with PDTC individually although several authors
recommend it in all patients with 131I uptake [5, 18].
Seven patients (50%) in our group were treated with
external radiotherapy — one with palliative radiother-
apy on the neck and mediastinum as the only element
of management with short survival time (7.1%). The
remaining six patients (42.9%), all pT4 and/or N1, were
qualified for postoperative external beam radiotherapy
to the neck and mediastinum areas. In this sub-group
four patients underwent not-radical surgery treatment.
One of them (1/6; 16.7%) died of thyroid carcinoma af-
ter 30 months, two patients (2/6; 33.3%) have been un-
der observation for over 5 years, and one of them pre-
sented distant metastases to the lung in the sixth year
of follow-up.
External beam radiotherapy is an open question in
PDTC. Individual qualification is recommended as no
improvement in PDTC 5-year survival has been docu-
mented, although it was administrated significantly
more frequently than in patients with WDTCs [18, 19,
32, 33]. Sanders Jr. et al. analyzed the efficacy of exter-
nal radiotherapy at high risk of recurrence and recom-
mended external beam treatment for PDTC to be con-
sidered in T3 tumours without distant metastases, in all
T4 tumours, and in cases of regional lymph node in-
volvement, regardless of T [5]. He went on to say that if
surgery is thought to be complete, 131I treatment should
be given first, before radiotherapy, and if surgery was
not radical he suggested radiotherapy postoperatively.
Most of data regarding the use of chemotherapy in
thyroid cancer are based on studies performed for ATC
[3]. Chemotherapy in patients with PDTCs ought to be
considered individually. The available studies are usu-
ally short and concern inoperable PDTCs [3]. The ad-
ministration of methotrexate, vinblastine, doxorubicin,
and bleomycin in monotherapy has been proposed [3,
18, 19]. Combination therapy composed of chemother-
apy and external radiotherapy at the same time is con-
sidered as an experimental treatment [18, 19]. Molecu-
lar guided therapy is the only element of controlled clin-
ical studies [19].
One patient in our study (7.1%) with distant me-
tastases to the lung was referred for chemotherapy. He
was treated with doxorubicin and cisplatin and obtained
incomplete remission.
Conclusions
Poorly differentiated thyroid carcinoma is still a chal-
lenge both for pathologists and clinicians. Infrequent
prevalence, more aggressive course, and poorer prog-
nosis constitute major problems for clinicians.
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